These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 27317851)
21. Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. Gao F; Zheng KI; Chen SD; Lee DH; Wu XX; Wang XD; Targher G; Byrne CD; Chen YP; Kim W; Zheng MH Clin Transl Gastroenterol; 2021 Mar; 12(3):e00321. PubMed ID: 33704100 [TBL] [Abstract][Full Text] [Related]
22. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712 [TBL] [Abstract][Full Text] [Related]
23. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881 [TBL] [Abstract][Full Text] [Related]
24. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers. Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042 [TBL] [Abstract][Full Text] [Related]
25. [Polymorphism rs738409 in PNPLA3 is associated with inherited susceptibility to non-alcoholic fatty liver disease]. Xu J; Xin YN; Lü WH; Lin ZH; Zhang DD; Zhang M; Dong QJ; Jiang XJ; Xuan SY Zhonghua Gan Zang Bing Za Zhi; 2013 Aug; 21(8):619-23. PubMed ID: 24119744 [TBL] [Abstract][Full Text] [Related]
26. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400 [TBL] [Abstract][Full Text] [Related]
27. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype. Mazzini FN; Cook F; Gounarides J; Marciano S; Haddad L; Tamaroff AJ; Casciato P; Narvaez A; Mascardi MF; Anders M; Orozco F; Quiróz N; Risk M; Gutt S; Gadano A; Méndez García C; Marro ML; Penas-Steinhardt A; Trinks J Metabolomics; 2021 Jun; 17(7):58. PubMed ID: 34137937 [TBL] [Abstract][Full Text] [Related]
28. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. Yilmaz Y; Eren F Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1292-5. PubMed ID: 25171027 [TBL] [Abstract][Full Text] [Related]
29. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A; Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076 [TBL] [Abstract][Full Text] [Related]
30. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Vilar-Gomez E; Yasells-Garcia A; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Villa-Jimenez O; Friedman SL; Diago M; Romero-Gomez M Hepatology; 2016 Jun; 63(6):1875-87. PubMed ID: 26849287 [TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. Jung KY; Cho SY; Kim HJ; Kim SB; Song IH J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936 [TBL] [Abstract][Full Text] [Related]
32. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis. Cabré N; Luciano-Mateo F; Baiges-Gayà G; Fernández-Arroyo S; Rodríguez-Tomàs E; Hernández-Aguilera A; París M; Sabench F; Del Castillo D; López-Miranda J; Menéndez JA; Camps J; Joven J Aliment Pharmacol Ther; 2020 Feb; 51(3):374-387. PubMed ID: 31825539 [TBL] [Abstract][Full Text] [Related]
38. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy. Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116 [TBL] [Abstract][Full Text] [Related]
39. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761 [TBL] [Abstract][Full Text] [Related]
40. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. Dong S; Zhan ZY; Cao HY; Wu C; Bian YQ; Li JY; Cheng GH; Liu P; Sun MY World J Gastroenterol; 2017 Apr; 23(15):2771-2784. PubMed ID: 28487615 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]